Contributions
Abstract: P673
Type: Poster
Abstract Category: Therapy - disease modifying - Neuroprotection
Aim: The aim of this study was to evaluate the association of serum 25-hydroxyvitamin D(25(OH)D) with disability and frequency of relapses in relapsing-remitting multiple sclerosis(MS)patients.
Methods: The study included 100 patients with relapsing-remitting MS who were receving immune-modulating drugs and no vitamin D supplementation.The concentration of 25 (OH)D was measured in January 2014-January 2016.The level of disability was assessed twice according to the Expanded Disability Status Scale(EDDS).The 25(OH)D levels were compared with the occurrence of relapses and the level of disability.
Result: 100 patients were diagnosed with relapsing remitting multiple sclerosis between january 2014 january 2016. They are evaluated for 25 OH D levels. 30 healthy volunteer were taken to the study. There are 30 healhy control. There are 70 women, 30 men. Female/male ratio is 2.3/1. Average EDSS score was 2. Age interval of male patients was 22 - 65. Average (OH) D level in male patients was 8.
Average age in 70 women was 40. The age interval varies 24 - 67. Average (25 OH) D was 11. The interval of (25 OH) D was 4 - 187.
Conclusion: Male and female multiple sclerosis patients were compared with the control group. (25 OH) D level were lower in these patients. We observed that (25 OH) D supplementation along with the immunomodulators were effective on the relapse and symptoms.
Discussion: Vitamin D3 played an important role in regulating the genes. Vitamin D3 deficiency increases the risk of cancer, osteoporosis, diabetes, multiple sclerosis, hypertension, immunological and inflamatory diseases. In this study we found low 25(OH)D) levels in MS patients.
Disclosure: The level of Vıtamın D3 was found in low concantratıon in the Relapsing-remitting Multiple Sclerosis.
Abstract: P673
Type: Poster
Abstract Category: Therapy - disease modifying - Neuroprotection
Aim: The aim of this study was to evaluate the association of serum 25-hydroxyvitamin D(25(OH)D) with disability and frequency of relapses in relapsing-remitting multiple sclerosis(MS)patients.
Methods: The study included 100 patients with relapsing-remitting MS who were receving immune-modulating drugs and no vitamin D supplementation.The concentration of 25 (OH)D was measured in January 2014-January 2016.The level of disability was assessed twice according to the Expanded Disability Status Scale(EDDS).The 25(OH)D levels were compared with the occurrence of relapses and the level of disability.
Result: 100 patients were diagnosed with relapsing remitting multiple sclerosis between january 2014 january 2016. They are evaluated for 25 OH D levels. 30 healthy volunteer were taken to the study. There are 30 healhy control. There are 70 women, 30 men. Female/male ratio is 2.3/1. Average EDSS score was 2. Age interval of male patients was 22 - 65. Average (OH) D level in male patients was 8.
Average age in 70 women was 40. The age interval varies 24 - 67. Average (25 OH) D was 11. The interval of (25 OH) D was 4 - 187.
Conclusion: Male and female multiple sclerosis patients were compared with the control group. (25 OH) D level were lower in these patients. We observed that (25 OH) D supplementation along with the immunomodulators were effective on the relapse and symptoms.
Discussion: Vitamin D3 played an important role in regulating the genes. Vitamin D3 deficiency increases the risk of cancer, osteoporosis, diabetes, multiple sclerosis, hypertension, immunological and inflamatory diseases. In this study we found low 25(OH)D) levels in MS patients.
Disclosure: The level of Vıtamın D3 was found in low concantratıon in the Relapsing-remitting Multiple Sclerosis.